US Stock MarketDetailed Quotes
SRZN Surrozen
- 9.3000
- +0.4000+4.49%
Close Nov 21 16:00 ET
30.22MMarket Cap-548P/E (TTM)
9.7500High8.7900Low22.70KVolume9.6600Open8.9000Pre Close207.27KTurnover1.47%Turnover RatioLossP/E (Static)3.25MShares16.190052wk High5.33P/B14.37MFloat Cap5.999952wk Low--Dividend TTM1.55MShs Float210.0000Historical High--Div YieldTTM10.79%Amplitude4.5000Historical Low9.1320Avg Price1Lot Size
About Surrozen Company
Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.
Company Profile
SymbolSRZN
Company NameSurrozen
Listing DateAug 12, 2021
Founded2015
CEOMr. Craig C. Parker
MarketNASDAQ
Employees42
Fiscal Year Ends12-31
Address171 Oyster Point Boulevard,Suite 400
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-489-9000
Websitehttp://www.surrozen.com
Company Executives
- Name
- Position
- Salary
- Craig C. Parker
- President, Chief Executive Officer and Director
- 1.17M
- Charles Williams
- Chief Operating Officer, Chief Financial Officer, Corporate Secretary and Principal Accounting Officer
- 675.53K
- Dr. Yang Li, PhD
- Executive Vice President, Research
- 576.73K
- Dr. David J. Woodhouse, PhD
- Chairman of the Board
- 73.05K
- Christopher Y. Chai
- Independent Director
- 62.05K
- Dr. Anna Berkenblit, M.D.
- Independent Director
- 48.05K
- Dr. Mace Rothenberg, M.D.
- Independent Director
- 47.05K
- Dr. Shao-Lee Lin, M.D.,PhD
- Independent Director
- 48.05K
- Eric H. Bjerkholt
- Independent Director
- 56.94K
- Dr. Mary Haak-Frendscho, PhD
- Independent Director
- 53.05K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data